Business Context and Reporting Period
Company: Inovio Pharmaceuticals, Inc. (INO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Inovio is a biotechnology company developing DNA medicines and proprietary CELLECTRA delivery devices. The lead candidate, INO-3107, is an investigational DNA medicine for recurrent respiratory papillomatosis (RRP). The company submitted a Biologic License Application (BLA) for INO-3107 in November 2025, accepted by the FDA in December 2025 with a PDUFA target date of October 30, 2026. The company is currently preparing for a potential commercial launch.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | As of June 30, 2026 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(6.0) million | $(25.7) million | N/A |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.34) | N/A |
| Operating Expenses | $18.6 million | $40.6 million | N/A |
| Cash, Cash Equivalents & Short-Term Investments | N/A | N/A | $36.7 million |
| Working Capital | N/A | N/A | $(2,000) |
| Accumulated Deficit | N/A | N/A | $(1.84) billion |
| Common Stock Warrant Liabilities | N/A | N/A | $25.0 million |
Note: The company recorded a non-cash gain of $13.9 million for the quarter and $18.0 million for the six months due to the change in fair value of common stock warrant liabilities, primarily driven by the expiration of July 2025 Series A warrants and valuation adjustments.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased significantly from $(23.5) million in the prior year quarter to $(6.0) million, and from $(43.2) million in the prior year six-month period to $(25.7) million. This improvement is largely attributable to a $18.0 million non-cash gain from warrant liability revaluation in the current six-month period, compared to a $1.8 million gain in the prior year period.
- Operating Expenses: Total operating expenses decreased by approximately 19% year-over-year for the six-month period ($40.6 million vs. $48.2 million). This was driven by lower employee compensation, reduced engineering services, and lower expensed inventory, partially offset by higher severance and outside services related to INO-3107.
- Investment Write-down: The company recorded a $2.1 million loss on its investment in affiliated entity Plumbline Life Sciences, Inc. (PLS) due to a reclassification to Level 3 fair value and a determination that the fair value was $0 following a trading suspension of PLS stock.
- Financing Activity: The company raised $16.1 million in net proceeds from an April 2026 public offering and $1.1 million from At-The-Market sales during the six months ended June 30, 2026.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern beyond the first quarter of 2027. Current cash resources, combined with proceeds from a subsequent July 2026 offering ($18.3 million), are expected to fund operations only through late Q1 2027.
- Regulatory Outlook: The FDA is reviewing the BLA for INO-3107 under the accelerated approval pathway. While the company believes it meets criteria, the FDA has not yet confirmed eligibility. If accelerated approval is denied, a Phase 3 trial may be required, incurring substantial costs.
- Competition: PAPZIMEOS received full FDA approval for RRP in August 2025. Inovio must demonstrate that INO-3107 provides a clinically meaningful benefit over PAPZIMEOS to secure accelerated approval.
- Legal Proceedings: The company is facing a shareholder class action lawsuit alleging false statements regarding the FDA review timeline for INO-3107. Additionally, a trial is scheduled for October 2026 regarding a breach of contract dispute with former manufacturer VGXI.
- Unusual Items: The financial results are significantly impacted by the non-cash gain from warrant liability revaluation and the write-down of the PLS investment. These items do not reflect cash operating performance.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $36.7 million cash balance plus the $18.3 million July 2026 offering proceeds to fund operations through Q1 2027, considering the "substantial doubt" disclosure.
- Warrant Liability Volatility: Assess the impact of the $25.0 million warrant liability on the balance sheet and the potential for future non-cash gains or losses based on stock price volatility.
- INO-3107 Approval Status: Monitor FDA communications regarding the accelerated approval eligibility and the potential requirement for a confirmatory Phase 3 trial.
- Litigation Exposure: Review the status of the shareholder class action and the VGXI litigation trial scheduled for October 2026.
- Investment in PLS: Confirm the valuation methodology and potential for further impairment regarding the Plumbline Life Sciences investment.